CliffBio
small molecule

DAPTOMYCIN

DAPTOMYCIN

Loss of exclusivity—loss of exclusivity
CompanyMaia →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAPTOMYCIN
Active ingredientDAPTOMYCIN
Strength350MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2024
Marketing statusDISCN

More from Maia

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DAPTOMYCIN patent cliff — loss of exclusivity — | CliffBio